Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 472 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Testing Clear all
Completed Not applicable Interventional

Dog Hair Extract Study

NCT01343420
View directory record Official record
Conditions
Potency of Dog Hair Extract
Interventions
Dog Hair Extract, ALK-Abelló, Inc.
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 20, 2026, 2:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Patient Forward Access to Clinical and Technological Research: Genetic Influences on Cancer and Atopic Dermatitis

NCT04362852
View directory record Official record
Conditions
Eczema/Atopic Dermatitis, Cancer
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 20, 2026, 2:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Randomized Evaluation of Ten Allergy Skin Prick Test Devices

NCT03509766
View directory record Official record
Conditions
Allergic Rhinitis, Asthma, Food Allergy, Skin Testing
Interventions
Histamine skin testing
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 20, 2026, 2:20 PM EDT
Suspended Phase 3 Interventional

Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial

NCT06671912
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Anastrozole, Letrozole, Exemestane, Tamoxifen, Mammogram, Magnetic Resonance Imaging, Dual X-ray Absorptiometry, Biospecimen Collection, Questionnaire Administration
Drug · Procedure · Biological + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
728
States / cities
Anchorage, Alaska • Gilbert, Arizona • Goodyear, Arizona + 559 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 2:20 PM EDT
Completed No phase listed Observational

X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Carrier Outlook Toward Reproduction Survey

NCT01398813
View directory record Official record
Conditions
Hypohidrotic Ectodermal Dysplasia, X-Linked Hypohidrotic Ectodermal Dysplasia
Interventions
Not listed
Lead sponsor
Edimer Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Oct 20, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis

NCT04015518
View directory record Official record
Conditions
Palmoplantar Pustulosis (PPP)
Interventions
Spesolimab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Birmingham, Alabama • Beverly Hills, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 20, 2026, 2:20 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Cultured Circulating Tumor Cells in Prostate and Other Cancers

NCT02123862
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Oscar Goodman, Jr.
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 20, 2026, 2:20 PM EDT
Enrolling by invitation Phase 3 Interventional

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

NCT03683186
View directory record Official record
Conditions
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions
Ralinepag
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
48
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 2:20 PM EDT
Recruiting Not applicable Interventional

Weight Management After Cancer for Survivors in Rural Communities

NCT07426952
View directory record Official record
Conditions
Breast Cancer Survivorship, Weight Management, Cardiovascular (CV) Risk, Breast Cancer
Interventions
WeCan-Rural Program
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
5
States / cities
Durham, North Carolina • Henderson, North Carolina • Laurinburg, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 2:20 PM EDT
Not listed Phase 2 Interventional

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

NCT03412643
View directory record Official record
Conditions
HER2-negative Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Weekly Paclitaxel, Trastuzumab, Pertuzumab, Celcuity CELx HSF
Drug · Diagnostic Test
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
43
States / cities
Colton, California • Miami Beach, Florida • Orlando, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 20, 2026, 2:20 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Vanguard Study: Testing a New Way to Screen for Cancer

NCT06995898
View directory record Official record
Conditions
Bladder Carcinoma, Breast Carcinoma, Colorectal Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Liver Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma
Interventions
Biospecimen Collection, Device Usage, Electronic Health Record Review, Multi-Cancer Detection Test, Questionnaire Administration
Procedure · Device · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
45 Years to 75 Years
Enrollment
24,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
45
States / cities
Pleasanton, California • Cheyenne Wells, Colorado • Denver, Colorado + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 2:20 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Improving Care After Inherited Cancer Testing

NCT04763915
View directory record Official record
Conditions
Inherited Cancer Syndrome, Prostate Cancer, Colorectal Cancer, Endometrial Cancer, Breast Cancer
Interventions
Correlative Studies (Survey), Correlative Studies (Interview), GeneSHARE, LivingLabReport, Standard-of-care & Adaptive Intervention, Access to Education Materials
Other · Behavioral
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 20, 2026, 2:20 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Non-Invasive Testing to Evaluate Wound Healing in Diabetes

NCT04232631
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
SnapshotNIR, Kent Imaging
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 20, 2026, 2:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Eligibility Screening for the NIH Intramural Research Program Clinical Protocols

NCT00026754
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Lung Cancer, Sarcoma, Melanoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Month and older
Enrollment
19,522 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 20, 2026, 2:20 PM EDT
Completed Not applicable Interventional

Adaptation and Pilot Testing of a Mindfulness-Based Insomnia and Symptom Management Intervention for Women With Breast Cancer Receiving Treatment in Rural Medically Underserved Areas

NCT06529120
View directory record Official record
Conditions
Breast Cancer
Interventions
Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Prince Frederick, Maryland • Henderson, North Carolina • Laurinburg, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 20, 2026, 2:20 PM EDT
Active, not recruiting Phase 2 Interventional

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
Interventions
Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1405
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 2:20 PM EDT
Active, not recruiting Phase 4 Interventional

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

NCT06013969
View directory record Official record
Conditions
Generalized Pustular Psoriasis
Interventions
Spesolimab
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Irvine, California • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 2:20 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Determination of Kidney Function

NCT00001978
View directory record Official record
Conditions
Kidney Disease, Proteinuria, Autoimmune / Connective Tissue Diseases
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
7 Years and older
Enrollment
456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1989 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 20, 2026, 2:20 PM EDT
Terminated No phase listed Observational

CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice

NCT02900248
View directory record Official record
Conditions
Neoplasms, Lung Neoplasms, Colon Neoplasms, Breast Neoplasms, Pancreatic Neoplasms, Prostate Neoplasms, Kidney Neoplasms, Liver Neoplasms, Rectal Neoplasms, Hematologic Neoplasms, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Bladder Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Brain Neoplasms, Biliary Tract Neoplasms, Head and Neck Neoplasms, Uterine Cervical Neoplasms, Skin Neoplasms, Melanoma, Gastric Neoplasms, Anal Neoplasms, Sarcoma
Interventions
Provider determined
Other
Lead sponsor
CureOne
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 20, 2026, 2:20 PM EDT
Recruiting No phase listed Observational

BostonGene and Exigent Genomic INsight Study

NCT06272864
View directory record Official record
Conditions
Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
Interventions
Not listed
Lead sponsor
BostonGene
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Rogers, Arkansas • Stockton, California • Fort Wayne, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 20, 2026, 2:20 PM EDT
Completed Not applicable Interventional Results available

Antimicrobial Stewardship Through MRSA Diagnosis in Emergency Department (ED) Patients With Abscesses

NCT01523899
View directory record Official record
Conditions
Cutaneous Abscess
Interventions
Xpert MRSA/SA SSTI, Standard culture
Device · Diagnostic Test
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 20, 2026, 2:20 PM EDT
Recruiting Phase 1 Interventional

A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo

NCT06625177
View directory record Official record
Conditions
Vitiligo
Interventions
TEV-53408
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Fremont, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis

NCT03798366
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
GLPG1690, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Los Angeles, California • Boca Raton, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 20, 2026, 2:20 PM EDT
Not listed Phase 4 Interventional

Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy

NCT02270970
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
belimumab
Biological
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
16 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 20, 2026, 2:20 PM EDT